Covid-19 man­u­fac­tur­ing roundup: Co­v­ax, In­di­an man­u­fac­tur­er at odds over vac­cine sup­ply; EU plan­ning sur­plus on shot pro­duc­tion

Co­v­ax, which ships Covid-19 vac­cines to low- and mid­dle-in­come na­tions, is call­ing for more In­di­an-made dos­es of As­traZeneca’s vac­cine, Reuters re­port­ed, as a key man­u­fac­tur­er plans to halve the vac­cine’s pro­duc­tion tem­porar­i­ly un­til it gets more or­ders.

The Serum In­sti­tute of In­dia said up­take has slowed sharply and told an In­di­an tele­vi­sion sta­tion that Co­v­ax was tak­ing in few­er dos­es than of­fered. CEO Adar Poon­awal­la said up­take is ex­pect­ed to kick up next quar­ter, but a spokesper­son for Gavi, which is pro­vid­ing low-cost shots world­wide as part of a col­lab­o­ra­tion with Co­v­ax, told Reuters the or­ga­ni­za­tion is still re­ceiv­ing “ro­bust de­mand” for Co­v­ishield.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER